Event Program
11:10 am - 11:15 am
EST
Opening Remarks
11:15 am - 12:00 pm
EST
Roundtable1: The Benefits of Deeper, Long-Term Investment in Underserved Patient Populations at the Community Level
Molly MacDonald -
CEO/Founder,
The Pink Fund
Dr. Kevin Knopf MD - Division Chief Hematology/Oncology, Highland Hospital
Investment in underserved communities benefits trial sponsors, site hosts, and most importantly, patients. The impact of relationship building within underserved communities can not be underestimated. In order to improve rates of enrollment and trial awareness and to dispel mistrust in patient populations from this community, stakeholders must understand the crucial importance of forging a long lasting relationships rather than short term incentives for trial participation.
12:00 pm - 12:15 pm
EST
Q&A session
12:15 pm - 1:00 pm
EST
Case Study: Implementing Diversity-Orientated Criteria & Metrics in Clinical Trial Design
Melissa Gonzales -
Inclusion Principal, External Partnering,
Genentech
Salah El-Saheb PharmD - Clinical Operations Leader, Genetech
From the implementation of technology to expand into underserved areas for clinical trials, to achieving c-suite buy-in to make diversity an organizational priority. Develop actionable strategies for trial planning, design and execution alongside, ideally, a diversity mandate within organizational strategy for clinical trials.
1:00 pm - 1:15 pm
EST
Q&A session
1:15 pm - 2:00 pm
EST
Roundtable 3: Overcoming Social, Economic & Logistical Barriers to Trial Enrollment, Engagement & Retention
Marianne Gandee -
Senior Director, Team Lead, Advocacy and Professional Relations, Pfizer Oncology,
Pfizer
Lorena Kuri - Head of Diversity Strategy, Bristol Myers Squibb
LaTasha Lee PhD. - Vice President, Social and Clinical Research & Development, National Minority Quality Forum
Marvella E. Ford, PhD - Associate Director, Population Sciences and Cancer Disparities, Hollings Cancer Center
Explore how stakeholders can collaborate, engage and implement novel strategies to truly overcome socio-economic and logistical barriers to enrollment, engagement and retention for underrepresented patient populations on clinical trials.
Marianne Gandee
Senior Director, Team Lead, Advocacy and Professional Relations, Pfizer OncologyPfizer
LaTasha Lee PhD.
Vice President, Social and Clinical Research & DevelopmentNational Minority Quality Forum
Marvella E. Ford, PhD
Associate Director, Population Sciences and Cancer DisparitiesHollings Cancer Center
